Evidence map›Paper›PMID 40842496›Full record

ArticleFrontiers in endocrinology2025

Association of the atherogenic index of plasma and high-sensitivity C-reactive protein with incident cardiovascular disease: evidence from a national cohort of middle-aged and older Chinese adults.

Ping-An Lian, Fei Xie, Wei Zhang, Shuai Cheng, Yun-Fei Zhao, Lin Li, Shan-Fu Liang, Zhan-Zhan Zhu, Jun-Yue Zhang, Jiao-Jiao Cui and 3 more

Abstract read
In one paragraph

Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Ping-An LianDepartment of Cardiology, Seventh People's Hospital of Zhengzhou, Zhengzhou, Henan, China.
Fei XieDepartment of Cardiology, Seventh People's Hospital of Zhengzhou, Zhengzhou, Henan, China.
Wei ZhangDepartment of Cardiology, Seventh People's Hospital of Zhengzhou, Zhengzhou, Henan, China.
Shuai ChengDepartment of Cardiology, Seventh People's Hospital of Zhengzhou, Zhengzhou, Henan, China.
Yun-Fei ZhaoDepartment of Cardiology, Seventh People's Hospital of Zhengzhou, Zhengzhou, Henan, China.
Lin LiDepartment of Cardiology, Seventh People's Hospital of Zhengzhou, Zhengzhou, Henan, China.
Shan-Fu LiangDepartment of Cardiology, Seventh People's Hospital of Zhengzhou, Zhengzhou, Henan, China.
Zhan-Zhan ZhuDepartment of Cardiology, Seventh People's Hospital of Zhengzhou, Zhengzhou, Henan, China.
Jun-Yue ZhangDepartment of Cardiology, Seventh People's Hospital of Zhengzhou, Zhengzhou, Henan, China.
Jiao-Jiao CuiDepartment of Cardiology, Seventh People's Hospital of Zhengzhou, Zhengzhou, Henan, China.
Jie DuBiotherapy Institute, Henan Academy of Innovations in Medical Science, Zhengzhou, Henan, China.
Lei YinDepartment of Ophthalmology, Seventh People's Hospital of Zhengzhou, Zhengzhou, Henan, China.
Shen-Wei ZhangDepartment of Cardiology, Seventh People's Hospital of Zhengzhou, Zhengzhou, Henan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The atherogenic index of plasma (AIP), an emerging biomarker of lipid dysregulation, and high-sensitivity C-reactive protein (hs-CRP), an established marker of inflammation, are both implicated in the development of cardiovascular disease (CVD). However, their joint impact on CVD risk and the underlying mediation mechanisms remain unclear. Methods: This study used data from the China Health and Retirement Longitudinal Study (CHARLS), including 8,763 adults aged ≥45 years with up to 9 years of follow-up. Baseline AIP and hs-CRP levels were measured, and participants were divided into four groups based on the AIP median and hs-CRP threshold (1 mg/L). Multivariable Cox models assessed associations with CVD. Mediation analyses examined direct and indirect effects, including bidirectional mediation. Additive interaction was evaluated using the relative excess risk due to interaction (RERI), and predictive performance was assessed via Receiver Operating Characteristic Curve (ROC) curve analysis. Results: A total of 1,693 participants developed CVD during the follow-up period. Higher levels of AIP and hs-CRP were independently associated with CVD. Joint analysis showed that, compared with individuals with AIP below the median and hs-CRP <1 mg/L, those with elevated levels of both AIP and hs-CRP had the highest risks of CVD (HR: 1.655; 95% CI: 1.455-1.883), heart disease (HR: 1.402; 95% CI: 1.207-1.628), and stroke (HR: 2.207; 95% CI: 1.771-2.749). These associations remained significant after adjustment for potential confounders, although the effect sizes were attenuated. Notably, the effect of hs-CRP on increased CVD risk was more pronounced among individuals with higher AIP levels. Mediation analysis revealed that hs-CRP mediated 6.6% of the association between AIP and CVD ( Conclusions: Elevated levels of AIP and hs-CRP were independently and jointly associated with an increased risk of cardiovascular disease, particularly stroke. The observed mutual mediation effects and potential additive interaction suggest that lipid metabolism and inflammation may be interconnected in the pathophysiological processes underlying cardiovascular risk. These findings highlight the potential value of incorporating both biomarkers into cardiovascular risk assessment models to enhance early identification and prevention strategies among middle-aged and older adults.

Indexed as

AtherosclerosisCardiovascular DiseasesC-Reactive ProteinAgedBiomarkersChinaCohort StudiesEast Asian PeopleFemaleFollow-Up StudiesHumansIncidenceLongitudinal StudiesMaleMiddle AgedRisk FactorsBiomarkersC-Reactive Proteinatherogenic index of plasmacardiovascular diseaseCHARLSC-reactive proteininflammationlongitudinal cohort study

Identifiers

PMID40842496
PMCPMC12364642

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.